Prostaglandin E$_2$ promotes post-infarction cardiomyocyte replenishment by endogenous stem cells

Ying-Chang Hsueh$^{1,2,†}$, Jasmine M F Wu$^{1,2,†}$, Chun-Keung Yu$^{1,3}$, Kenneth K Wu$^{4}$ & Patrick C H Hsieh$^{1,2,5,*}$

Abstract

Although self-renewal ability of adult mammalian heart has been reported, few pharmacological treatments are known to promote cardiomyocyte regeneration after injury. In this study, we demonstrate that the critical period of stem/progenitor cell-mediated cardiomyocyte replenishment is initiated within 7 days and saturates on day 10 post-infarction. Moreover, blocking the inflammatory reaction with COX-2 inhibitors may also reduce the capability of endogenous stem/progenitor cells to repopulate lost cells. Injection of the COX-2 product PGE$_2$ enhances cardiomyocyte replenishment in young mice and recovers cell renewal through attenuating TGF-$
\beta$1 signaling in aged mice. Further analyses suggest that cardiac stem cells are PGE$_2$-responsive and that PGE$_2$ may regulate stem cell activity directly through the EP2 receptor or indirectly by modulating its micro-environment in vivo. Our findings provide evidence that PGE$_2$ holds great potential for cardiac regeneration.

Keywords  aging; cardiac regeneration; cyclooxygenase 2; genetic fate-mapping; inflammation

Subject Categories  Cardiovascular System; Stem Cells

Results

Endogenous stem/progenitor cell-mediated cardiomyocyte replenishment is initiated within 7 days post-MI

To determine the most critical time period for cardiomyocyte replenishment, we used the M/Z mice to trace endogenous stem/progenitor cell-driven cardiomyocyte replenishment upon injury (Fig 1A and B, Supplementary Fig S1) (Hsieh et al, 2007; Loffredo Francesco et al, 2011; Malliaras et al, 2013). Compared with the sham group, there were ~10% and ~20% of GFP cardiomyocytes renewed at the border zone on day 7 and 20% of cardiomyocytes are replenished by endogenous stem/progenitor cells in the peri-infarct border zone after myocardial infarction (MI) in mice (Hsieh et al, 2007; Loffredo Francesco et al, 2011; Malliaras et al, 2013; Senyo et al, 2013). Interestingly, a recent study by Senyo et al reported that ~20% of pre-existing cardiomyocytes at the border zone undergo cell cycle although among them, only 3.2% of cells complete the cell division (Senyo et al, 2013). These results imply that the majority of replenished cardiomyocytes may be originated from the endogenous stem/progenitor cells. Nevertheless, a therapy promoting endogenous stem cells to repair injury after MI, including systemic delivery of drugs, is still lacking. It also remains unclear the most critical time period to activate the stem cell-driven cardiomyocyte replenishment. Answers to these questions will offer opportunities for developing new de novo treatments.

In this study, we used the cardiac specific tamoxifen-inducible Cre-LoxP MerCreMer/ZEG (M/Z) transgenic mice to delineate the underlying mechanism initiating stem/progenitor cell-modulated cardiac repair and to investigate the regenerative efficiency in young and aged mice. Furthermore, we aimed to identify a pharmacological intervention that improves the cardiac repair efficiency after MI.
day 10 post-MI, respectively (Fig 1C). The cell replacement saturated on day 10 and leveled off until the third month after MI. β-Gal staining and cell quantification in the remote area showed consistent results (Fig 1C and D). These findings are in agreement with previous reports showing that transplanted or reidentified cardiac stem cells are capable of differentiating into cardiomyocytes within 7–14 days after MI (Oh et al., 2003; Rota et al., 2007; Smart et al., 2011).

**Early COX-2 activity is required for post-infarction cardiomyocyte replenishment**

MI-induced cyclooxygenase (COX)-2 expression and prostaglandin E2 (PGE2) production in the heart provide a cardiac protective effect (Degousee et al., 2008; Wang et al., 2009; Wong et al., 1998; Xiao et al., 2004). To explore its connection with cardiomyocyte repopulation, mice were treated with Indomethacin, a pan-COX pathway inhibitor (Goessling et al., 2009) (Fig 2A). At the border zone, the cardiomyocyte restoration rate dropped by ~10% upon Indomethacin administration (Fig 2B, Supplementary Fig S2). The same blocking effect was also observed in the remote area (Fig 2C). Furthermore, Indomethacin given during the first 5 days post-MI (Indo 5 D) sufficiently impaired cardiomyocyte replenishment at the border zone. However, it had no significant effect when given on day 6-14 post-MI (Indo L 9 D). Cardiomyocyte replenishment was also abolished upon treatment of Celecoxib, a selective COX-2 inhibitor (Lyons et al., 2011), for 14 days or within 5 days post-MI (Fig 2A and B, Supplementary Fig S3A and B).
Next, the mice were treated with the COX-2 downstream effectors prostaglandin E2 (PGE2), a pharmacological agent involved in stem cell-mediated tissue regeneration after injury (Goessling et al., 2009; Li et al., 2010) whose level increases in the heart after MI (Degousee et al., 2008). Our results indicated that treatment of PGE2, but not PGI2, significantly increased cardiomyocyte replenishment at the border zone by ~9% (Fig 2A and D, Supplementary Fig S2) and rescued cardiomyocyte repopulation by ~10% compared to that in Indomethacin or Celecoxib treatment alone (Fig 2B and D, Supplementary Fig S3B). A similar trend was observed in the remote area (Fig 2D and E). These findings imply that an early COX-2/PGE2 signaling is required for the induction of stem cell-driven cardiomyocyte replenishment.

PGE2 regulates cardiac stem cell differentiation

To determine whether PGE2 acts on cardiac stem/progenitor cells to promote cardiomyocyte differentiation, expression level of several known cardiac stem/progenitor cell markers quantified for identification of the PGE2-responsive gene. We discovered that Sca-1 expression peaked on day 3 post-MI and this level was further increased at the same time point upon PGE2 treatment but was
repressed by Indomethacin (Supplementary Fig S4). Sca-1 is a common marker co-expressed by several known cardiac stem/progenitor cell populations (Matsuura et al., 2009; Oh et al., 2003; Smart et al., 2011; Sturzu & Wu, 2011), for example c-Kit" cell population (Bailey et al., 2012; Rosenblatt-Velin et al., 2012). The c-Kit" cells originated from the heart or bone marrow are shown to possess cardiac repair capability (Ellison Georgina et al., 2013; Loffredo Francesco et al., 2011; Orlic et al., 2001; Rota et al., 2007). However, their ability to repair heart is attenuated upon loss of Sca-1 (Bailey et al., 2012; Rosenblatt-Velin et al., 2012). Furthermore, we observed that the expression pattern of the cardiac progenitor cell marker Nkx2.5 (Wu et al., 2006) is similar to that of Sca-1 (Supplementary Fig S5). Furthermore, PGE2 also elevated the expression of Nkx2.5 in Sca-1" cells (Supplementary Fig S6). We therefore sought to investigate the effect of PGE2 on stem cell-mediated cardiomyocyte replenishment by examining Sca-1" cell activities.

Because tamoxifen injection in M/Z mice leads to conversion of β-Gal to GFP in cardiomyocytes, we thought to take this advantage to examine cardiomyogenic differentiation ability of the cardiac Sca-1" cells. The tamoxifen injection was given to the M/Z mice after MI surgery, and therefore, only α-MHC" cells would express GFP (Supplementary Fig S7A). This experiment allowed us to determine whether Sca-1" cells possess the ability to differentiate into α-MHC" cells. Following MI surgery and tamoxifen injection for 3 days, Sca-1"/GFP" cells could be detected. The percentage of double positive cells was further increased upon PGE2 treatment (Supplementary Fig S7B and C). In addition, Sca-1"/α-MHC" cells were not observed before tamoxifen labeling and they do not arise from cardiomyocyte de-differentiation or fusion (Hsieh et al., 2007; Senyo et al., 2013) (Supplementary Fig S8A and B). These results reveal the potential contribution of cardiac Sca-1" stem/progenitor cells to cardiomyocyte replenishment after MI.

Following MI, M/Z system serves as a platform to assess the cardiomyocytes differentiated from endogenous stem/progenitor cells. To evaluate the cardiomyocyte differentiation ability of cardiac Sca-1" cells and the importance of PGE2 pathway during this process, the cells were isolated from wild-type and EP2−/− mice (Kennedy et al., 1999) for intramyocardial injection after MI surgery (Loffredo Francesco et al., 2011) (Supplementary Fig S11A). The EP2−/− transgenic mouse was chosen due to the expression of this PGE2 receptor was significantly induced in hearts after MI and in cardiac Sca-1" cells after PGE2 treatment (Supplementary Fig S9 and S10). Quantification of the GFP" and β-Gal" cardiomyocyte numbers revealed that injection of wild-type Sca-1" cells reduced both GFP" and β-Gal" cardiomyocyte numbers and that approximately 10% of the peri-infarct cardiomyocytes were GFP" and β-Gal", suggesting cardiomyocyte differentiation of the injected cardiac Sca-1" cells. In contrast, we did not observe such change in the M/Z mice receiving injection of EP2−/− Sca-1" cells (Fig 2F, Supplementary Fig S11). Together these results indicate that the PGE2/EP2 signaling may regulate the ability of cardiac Sca-1" cells to differentiate into cardiomyocytes. Results from in vitro culture also provided evidence that the expression of Nkx2.5 and cTnT was evidently improved in isolated cardiac small cells (cardiomyocyte-depleted cell fraction) and Sca-1" cells by PGE2 (Supplementary Fig S12B and C). Surprisingly, mature sarcomeric structure and spontaneously beating cells were seen in the cardiomyocyte-depleted small cells after PGE2 treatment (Supplementary Fig S12A and B, Movie S1), suggesting PGE2 may improve cardiomyocyte differentiation.

PGE2 modulates the post-infarction inflammatory response in the myocardium

PGE2 used to be considered as a pro-inflammatory molecule. However, it has been suggested that PGE2 may modulate the inflammatory microenvironment for tissue regeneration through regulating macrophage subtypes (Nemeth et al., 2009). Macrophages can be classified into M1 (CD45"CD11b"F4/80"Gr-1") and M2 (CD45"CD11b"F4/80"CD206") subtypes (Nishimura et al., 2009; Vandanmagsar et al., 2011). Interestingly, flow cytometry analysis revealed that PGE2 treatment elevated the number of M2 macrophages but reduced the number of M1 subtype after MI (Supplementary Fig S13A–C). Furthermore, quantitative RT-PCR indicated that PGE2 enhanced the expression of interleukin-10 (IL-10) (Nemeth et al., 2009), which is modulated by M2 macrophages (Nishimura et al., 2009; Vandanmagsar et al., 2011) (Supplementary Fig S14). Therefore, we speculate that PGE2 acts directly on not only the progenitor/stem cells but also the inflammatory cells such as macrophages to regulate the inflammatory microenvironment after MI.

PGE2 rescues the cardiomyocyte regeneration capacity of aged mice

Because the aged heart loses its regenerative ability (Senyo et al., 2013), we examined the degree of cardiomyocyte regeneration in old mice. In aged mice (>18 months), regardless of the same GFP labeling efficiency, MI itself did not induce evident cardiomyocyte replenishment at the border zone (Fig 3A and B). Surprisingly, PGE2 treatment successfully rescued the attenuated stem cell-mediated cardiomyocyte reconstitution at the border zone, but not in the remote area (Fig 3A and B). PGE2 also increased IL-10 expression in aged hearts (Fig 3C). Further investigation revealed that the expression of the aging-associated marker gene transforming growth factor β-1 (TGF-β1) (Carlson et al., 2008; Luo et al., 2010) declined in aged mice following PGE2 treatment (Fig 3D). Finally, administration of TGF-β Type I Receptor Kinase Inhibitor II (ALK5 Inhibitor II, ALK5i) (Ichida et al., 2009) restored cardiomyocyte replenishment in old mice (Fig 3E and F). Together these results suggest that high TGF-β1 activity may negatively regulate cardiomyocyte replenishment in aged hearts. Therefore, PGE2 not only augments cardiomyocyte replenishment in young mice but also rescues the self-regenerative function in aged mice.

Discussion

Although various cardiac stem/progenitor cell populations capable of differentiating into cardiomyocytes have been identified, a fundamental question remains unanswered. What initiation signal stimulates these cells to generate functional cardiomyocytes in situ after injury? It has been demonstrated that the deletion of COX-2 (Wang et al., 2009) or microsomal PGE2 synthase-1 (mPGES-1) (Degousee et al., 2008) adversely affects cardiac function after injury, suggesting a cardioprotective role of the COX-2 pathway. These findings are in line with our results where the inhibition of the COX-2 pathway
abrogates tissue repair mediated by endogenous stem/progenitor cells. Importantly, we provide evidence that early inflammatory response plays a key role in this process (Essers et al., 2009; Kyritsis et al., 2012; Li et al., 2010). Furthermore, we discover that PGE₂ treatment not only augments the efficiency of cardiomyocyte repopulation but also induces redistribution of M1/M2 macrophage ratio, implying the importance of PGE₂-modulated inflammatory microenvironment in this process (Nemeth et al., 2009).

The role of PGE₂ in modulating stem cell function has been reported in the bone marrow, where it regulates hematopoietic stem cell (HSC) homeostasis (North et al., 2007) and improves their functions, including survival and proliferation (Hoggatt et al., 2009). A recent study reported by Hoggatt et al demonstrates that PGE₂ facilitates retention of HSCs in the bone marrow and non-steroidal anti-inflammatory drug (NSAID) induces HSC egress (Hoggatt et al., 2013). Because Indomethacin and Celecoxib are NSAIDs, they may exert the same effect on HSCs. Based on these results, we suspect that the microenvironment in the cardiac infarct could be disturbed upon mobilization of un-differentiated HSCs, and consequently attenuates cardiomyocyte regeneration efficiency. However, administration of PGE₂ restores this regenerative machinery by acting on the cardiac stem/progenitor cells and inflammatory cells. We provide evidence to demonstrate that PGE₂ directly regulates cardiac Sca-1⁺ cells, implying a possible role of NSAID in mediating cardiac stem/progenitor cell mobilization. In addition, PGE₂ also increases the number of M2 macrophages. Based on these findings and previous studies showing PGE₂-dependent modulation of HSC activities, we speculate that how PGE₂ regulates HSCs after MI is also an important factor for cardiomyocyte regeneration.

On the basis of Senyo’s findings, several commentary articles have pointed out that the contribution of stem/progenitor cells to cardiac repair may be negligible (Mummery & Lee, 2013). Despite the use of ¹⁵N labeling system, one question that remains unsolved is the dilution of the GFP⁺ cardiomyocyte pool in the M/Z mice after MI (Senyo et al., 2013). Results in our study and others have demonstrated that the number of cardiomyocytes replenished by endogenous stem/progenitor cells at the infarct border zone is greater than the number of cells derived from the dividing pre-existing cardiomyocytes (Loffredo Francesco et al., 2011; Malliaras et al., 2013). Here, the results also reveal that the ability of stem/progenitor cells to give rise to cardiomyocytes could be modulated, suggesting a potential therapeutic application of the endogenous stem/progenitor cells for cardiac repair.

Figure 3. PGE₂ treatment restores cardiomyocyte replenishment in aged mice.

A, B Fourteen days post-MI, the hearts from aged mice (>18 months) were stained for GFP or β-Gal. Shown are representative images (A) and quantification (B) of GFP⁺ and β-Gal⁺ cardiomyocytes at the border zone and remote area.

C Quantitative RT-PCR analysis of IL-10 expression in response to PGE₂ treatment on day 3 after infarction at the injured region of old mice. n ≥ 3

D Effect of PGE₂ on TGF-β1 expression in the infarcted region of MI hearts in young and aged mice, examined on day 3 and day 7 after injury. n ≥ 3

E, F Vehicle or ALKi-treated hearts were harvested on day 14 post-MI for GFP and β-Gal staining. Shown are representative images (E) and quantification (F) of GFP⁺ and β-Gal⁺ cardiomyocytes at the border zone and remote area.

Data information: *P < 0.05. **P < 0.01; N.S., not significant. All scale bars: 100 μm. Sample size is indicated in the bar chart.

Materials and Methods

Mouse breeding

All experiments involving animals were conducted in accordance with the Guide for the Use and Care of Laboratory Animals, and all animal protocols have been approved by National Cheng Kung University. EP₂⁻/⁻, B6.129-Ptg2<sup>ptg2<sup>10ov</sup>/J mice were obtained from Jackson Laboratory. The double transgenic MerCreMer/ZEG (M/Z) mice were generated by crossbreeding MerCreMer and Z/EG mice (Jackson Laboratory), which have C57BL/6Sv129 and C57BL/6j (N7) background strains, respectively. The MerCreMer mice contain a tamoxifen-inducible Cre recombinase fusion protein driven by the
cardiomyocyte-specific α-MHC promoter. In Z/EG mice, GFP replaces constitutive β-Gal expression after the removal of a LoxP-flanked stop sequence by Cre.

**Surgery**

M/Z mice were subjected to experimental myocardial infarction (MI) 1 month after the last tamoxifen injection. MI was generated by ligating the left anterior descending coronary artery at 2–3 mm distal to the left atrial appendage. For immunohistological studies, mice were sacrificed and the hearts were harvested at different time points after MI surgery.

**Drug treatment**

To induce Cre recombination to achieve GFP labeling of cardiomyocytes, tamoxifen (Sigma) was dissolved in sunflower oil (Sigma) at a concentration of 5 mg/ml. The tamoxifen solution was injected intraperitoneal into M/Z mice daily at a dosage of 40 µg per 1 g body weight for 14 days. All experimental conditions were optimized prior to the PGE2, indomethacin and TGF-β Type I Receptor Kinase Inhibitor II (ALK5 Inhibitor II, 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, Merck) treatments. The mice treated with PGE2 or PGI2 (both from Sigma) were injected intraperitoneal with 3.33 ng of drug per 1 g of body weight dissolved in absolute ethanol twice daily. For the indomethacin treatment, mice were fed with water containing Indomethacin (Sigma, 15 µg/ml) for different periods of time. For the Indomethacin-containing water was changed every 3 days. The mice subjected to the Celecoxib (Sigma) treatment were injected intraperitoneal with 5 µg of drug per 1 g of body weight dissolved in absolute ethanol twice daily. For the Indomethacin treatment, mice were fed with water containing Indomethacin (Sigma, 15 µg/ml) for different periods of time. For the Indomethacin-containing water was changed every 3 days. The mice subjected to the Celecoxib (Sigma) treatment were injected intraperitoneal with 5 µg of drug per 1 g of body weight daily. For ALK5i treatment, aged mice were injected intraperitoneal once per day with 1 µg of drug per 1 g of body weight 1 day before surgery and continuously until day 10 post-MI. Celecoxib and ALK5i were dissolved in ethanol and DMSO, respectively.

**GFP* or β-Gal* cardiomyocyte counting**

All of the cellular quantifications were performed double-blindly to minimize personal bias. To achieve this, photo taken from the scar tissue was avoided so that the personnel performing cell quantification did not know if the photos were taken from the border zone or the remote area. For the cardiomyocyte cell counts, three sections from each heart, and 2 infarction border zones and 1 remote area from each section were analyzed at a magnification of 200× by light microscopy. Cells with visible sarcomere structures were analyzed, and the average number of cells counted was 171.8 ± 0.99 per photo image. For the small cardiac cell counts, more than five sections from each heart were analyzed at a magnification of 400× using fluorescence microscopy. The average number of cells counted was 17.01 ± 0.99 per photo image, and more than one hundred and fifty cells were analyzed from each heart. As quantification result is the averaged values calculated from the pictures taken from six border zone sections per heart, personal variation has been minimized.

**Immunohistochemistry and immunofluorescence microscopy**

The harvested hearts were fixed with 4% paraformaldehyde and embedded in paraffin. The sections were then immunostained with the following primary antibodies: mouse anti-GFP (1:500; MBL), rabbit anti-GFP (1:200; Abcam or GeneTex), rabbit anti-β-Gal (1:500; Invitrogen), mouse anti-ctnT (1:100; DSHB), and rat anti-Sca-1 PE (1:500; BD Bioscience). A DAB substrate kit (Vector Laboratories) was used for immunohistochemistry and appropriate secondary antibodies (Invitrogen or Abcam) were used for visualization under a fluorescence microscope. The plasma membrane was immunostained with wheat germ agglutinin (WGA, 5 µg/ml, Invitrogen) and 6,4-diamidino-2-phenylindole (DAPI, 1 µg/ml; Sigma) was used for nucleus staining.

**Extraction and preparation of total RNA for quantitative real-time PCR**

The total RNA isolated from the ischemic region of MI hearts was reverse transcribed using the SuperScript III (Invitrogen) system according to the manufacturer’s protocol. For quantitative PCR, the SYBR Green reagent (Maestrogen) was used according to the manufacturer’s protocol. For quantitative PCR, the SYBR Green reagent (Maestrogen) was used according to the manufacturer’s protocol. The analysis of relative gene expression was performed using the 2−ΔΔCT method. The sequence-specific primers designed for semi-quantitative PCR and real-time RT-PCR is listed in supplementary Table S1.

**Flow cytometry, cell isolation, culturing and immunocytochemistry staining**

Cardiomyocyte-depleted cardiac small cells were prepared as previously described with some modifications (Oh et al., 2003; Pfister et al., 2005). The minced heart tissue was digested with 0.1% collagenase B (Roche Molecular Biochemicals), 2.4 U/ml dispase II (Roche Molecular Biochemicals) and 2.5 mM CaCl2 at 37°C for 30 min and then filtered through a 40-µm filter. For isolation of cardiac Sca-1+ cells, the cardiac small cells were incubated with the Phycoerythrin (PE)-conjugated Sca-1+ antibodies (BD Bioscience) at 4°C for 30 minutes. The PE-labeled Sca-1+ cells were then sorted by the magnetic particles against PE (BD Biosciences). Respective isotype controls (BD Biosciences or GeneTex) were used as negative controls. Flow cytometry was performed using the FACScantor (BD). The FACSDiva (BD) and FlowJo software was used for data analysis. For cell culture, 3×10^5 cells were plated per well in a 6-well dish coated with 200 µg/ml fibronectin (Millipore). The cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (Invitrogen) supplemented with 10% FBS and penicillin/streptomycin at 37°C. The culture medium was changed 3 days after plating and the cells were treated with PGE2 (10 µM) for another 3 days. On day 10, immunocytochemistry (ICC) staining was performed. For ICC staining, the cells were fixed in 2% paraformaldehyde and blocked in 1% BSA. The cells were stained with the cTnT (1:100, DSHB) overnight at 4°C and membrane dye WGA (5 µg/ml, Invitrogen) at room temperature for 10 minutes.

**Flow cytometric analysis of macrophages**

Cardiomyocyte-depleted cardiac small cells were prepared as aforementioned method and 2×10^6 of cell were stained at 4°C in a total volume of 100 µl with the following antibodies: CD45-PE-Cy7 (1:100; BD), CD11b-PerCP-Cy5.5 (1:100; BD), F4/80-APC (1:20; AbD Serotec), Gr-1-FITC (1:100; eBioscience), CD206-PE (1:100;
PGE₂ promotes post-MI cardiomyocyte replenishment

Ying-Chang Hsueh et al

Conflict of interest

The authors declare that they have no conflict of interest.

References


The paper explained

Problem
It is known that the mammalian heart is capable of renewing cardiomyocytes and several cardiac stem/progenitor cells have been identified. However, little is known about the signal that stimulates endogenous stem cells to undergo differentiation, thus hindering the development of pharmacological interventions for treating heart injury.

Results
With an adult cardiomyocyte fate-mapping approach, we show that endogenous stem/progenitor cell-driven cardiac repair is initiated within 7 days and saturated on day 10 post-injury. The key to this stem/progenitor cell-dependent response is the COX-2-dependent inflammatory response in which PGE₂ plays a critical role. We identify that cardiac Sca-1+ cells are the population most responsive to PGE₂ stimulus and that EP2 signaling axis plays an important role in modulating cardiac stem cell activities. Interestingly, the aged heart is unable to self-repair but PGE₂ can restore this lost ability, possibly by lowering the expression of the aging marker gene, TGF-β1.

Impact
Here we identify the critical time period and the essential signal that activates the endogenous stem/progenitor cells for cardiac repair. Furthermore, we discover that PGE₂ can modulate stem cell activities. Following administration of PGE₂, the ability of stem/progenitor cells to replenish lost cardiomyocytes is improved in young mice and is restored in aged mice. Importantly, delivery of PGE₂ can be achieved via systemic injection, thus avoiding an invasive surgical approach. These results not only open a new avenue in the molecular mechanism controlling the post-MI inflammatory microenvironments but also pave the way for spontaneous cardiac repair and regeneration in the future.

Supplementary information for this article is available online: http://embomolmed.embopress.org

Data analysis
The results were statistically analyzed using either one-way ANOVA or t-tests. A result was considered to be statistically significant if the P < 0.05.

Acknowledgements
This work was supported by the National Research Program for Biopharmaceuticals [DOH101-TD-PB-111-TM027 and DOH101-TD-PB-111-TM028], the National Science Council (NSC101-2325-B-006-013) and the National Health Research Institutes (NHRI-EX101-10026S) in Taiwan. We also thank G. Yang (Cell-Bio Biotechnology Co., Ltd, Taipei, Taiwan) for assisting us with flow cytometer operation (SH800).

Author contributions
YCH designed and performed experiments, analyzed data and wrote the manuscript. JMFVW performed experiments, analyzed data and wrote the manuscript. CKY. and KKW designed experiments and analyzed data. PCHH designed experiments, analyzed data and wrote the manuscript.

© 2014 The Authors

EMBO Molecular Medicine  Vol 6 | No 4 | 2014

502


